Leading Ukrainian drug producer plans global expansion
Farmak, one of Ukraine’s largest drug producers, plans to significantly expand its sales and production capacities in the near future, according to local sources.
According to the company, as part of these plans, about 314 million hryvnia (about $40 million) will be invested in its further development and in particular in building a plant for the production of pharmaceutical substances, which will be located in the Sumy region of the country, as well as the construction of new scientific laboratories, and modernization of existing production facilities.
It is planned that, in addition to the company’s own investments, up to 50 million euros ($66.3 million) are expected to be provided by the Russian Bank of Reconstruction and Development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze